| Today's Big NewsJun 6, 2023 |
|
Montgomery County, MD, is a thriving innovation hub for the life sciences industry. Be Next and learn how companies are making their mark in the immunology capital next to the nation’s capital. Learn more. 
|
|
| By Gabrielle Masson As usual, ASCO occurred the first weekend in June in Chicago. Except this year, a superstar whose reputation precedes her put on a rivaling show right next door. |
|
|
|
| San Diego, CA |  |
|
|
By Gabrielle Masson Johnson & Johnson has seen response rates as high as 97% in multiple myeloma before but this time, it’s not for Carvykti. No, this time the healthcare giant’s pharmaceutical unit Janssen is shining the spotlight on a combo study for talquetamab and Tecvayli. |
By Max Bayer “It's a good time to be investing in and acquiring innovation,” Jazz Pharmaceuticals CEO Bruce Cozadd says, as the company scouts for deals at the BIO International Convention. |
By Nick Paul Taylor Ultragenyx Pharmaceutical has strengthened the evidence on its brittle bone disease prospect. The drug candidate triggered fast, significant improvements in bone mineral density, encouraging the biotech to race into the phase 3 portion of the study and try to wrap up enrollment this year. |
By Helen Floersh Researchers have uncovered new details about the mechanisms that cause plaques in arteries to rupture, paving the way for new tests to predict what patients are most at risk of a heart attack or stroke. |
By Nick Paul Taylor Erasca is cutting back its pipeline. The biotech has deprioritized several applications of one of its most advanced candidates after getting a look at lackluster data and put a KRAS inhibitor on the back burner in response to the “increasingly competitive landscape for small- and mid-cap biopharma companies.” |
By Annalee Armstrong Acepodia is ready to ante up its bet on cell therapy after turning over a brand new $100 million series D financing that will support the biotech's pipeline of medicines for solid tumors and hematological cancers. |
By Annalee Armstrong The FDA has signed off on an amended trial protocol for Theratechnologies’ solid tumors medicine, lifting its clinical hold and setting the Canadian biotech free to proceed. |
By Angus Liu Detailed data at ASCO 2023 showed how Merck's Keytruda and Roche's Tecentriq failed to improve outcomes for patients who had tried prior standard treatment in EGFR-mutated non-small cell lung cancer and kidney cancer, respectively. |
By Andrea Park Study results that Novocure presented at the American Society of Clinical Oncology annual meeting Tuesday scratched a seven-year itch: According to the company, it's the first phase 3 clinical trial in at least as long to detail a therapy’s ability to significantly improve the survival rate for patients with platinum-resistant, metastatic non-small cell lung cancer. |
By Frank Diamond Self-insured employers face a fairly new development: More younger people are driving high-cost claims, according to a new survey. |
By Eric Sagonowsky The pharma industry has voiced loud complaints about the Biden administration's Inflation Reduction Act, specifically focusing on a clause that will allow Medicare to negotiate the prices of top-selling pharmaceuticals. But now the industry is taking its arguments to the courts. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we discuss why generative AI can be "game-changing" in healthcare. We also take a second look at an episode on gender-affirming healthcare |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Save $500 when you Register before June 19th! 
|
|
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
